← All trials
NCT05364047
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2021
- Primary completion
- Oct 14, 2022
- Completion date
- Oct 31, 2023
- First posted
- May 6, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 144
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Central South UniversityOverall official - principal investigator
- Hangzhou Hospital of Traditional Chinese MedicineCollaborator
- Hangzhou Hospital of Traditional Chinese MedicineOverall official - principal investigator
- Yuncheng Central HospitalCollaborator
- Yuncheng Central HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.